X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
TEVA PHARMA
Dec-13
NATCO PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8772,840-   
Low Rs4242,467-   
Sales per share (Unadj.) Rs223.41,629.9-  
Earnings per share (Unadj.) Rs31.1101.8-  
Cash flow per share (Unadj.) Rs40.3233.6-  
Dividends per share (Unadj.) Rs5.0089.13-  
Dividend yield (eoy) %0.83.4 22.9%  
Book value per share (Unadj.) Rs219.51,810.5-  
Shares outstanding (eoy) m33.07848.00-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.6 178.8%   
Avg P/E ratio x20.926.1 80.3%  
P/CF ratio (eoy) x16.111.4 142.1%  
Price / Book Value ratio x3.01.5 202.1%  
Dividend payout %16.187.5 18.4%   
Avg Mkt Cap Rs m21,5042,250,219 1.0%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m1,1280-   
Avg. sales/employee Rs ThNM30,752.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM1,921.1-  
INCOME DATA
Net Sales Rs m7,3891,382,165 0.5%  
Other income Rs m1670-   
Total revenues Rs m7,5561,382,165 0.5%   
Gross profit Rs m1,793378,507 0.5%  
Depreciation Rs m304111,722 0.3%   
Interest Rs m36627,148 1.3%   
Profit before tax Rs m1,290239,637 0.5%   
Minority Interest Rs m461,089 4.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-157,308 0.0%   
Tax Rs m309-2,926 -10.6%   
Profit after tax Rs m1,02786,343 1.2%  
Gross profit margin %24.327.4 88.6%  
Effective tax rate %23.9-1.2 -1,960.4%   
Net profit margin %13.96.2 222.6%  
BALANCE SHEET DATA
Current assets Rs m3,681933,509 0.4%   
Current liabilities Rs m3,123814,099 0.4%   
Net working cap to sales %7.68.6 87.5%  
Current ratio x1.21.1 102.8%  
Inventory Days Days8991 98.6%  
Debtors Days Days5996 61.2%  
Net fixed assets Rs m7,685451,445 1.7%   
Share capital Rs m3313,402 9.7%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,2591,535,323 0.5%   
Long term debt Rs m955706,731 0.1%   
Total assets Rs m11,9573,158,689 0.4%  
Interest coverage x4.59.8 46.0%   
Debt to equity ratio x0.10.5 28.6%  
Sales to assets ratio x0.60.4 141.2%   
Return on assets %11.73.6 324.4%  
Return on equity %14.25.6 251.7%  
Return on capital %20.74.9 420.3%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,440220,245 0.7%  
From Investments Rs m-1,089-78,042 1.4%  
From Financial Activity Rs m-353-264,199 0.1%  
Net Cashflow Rs m-1-121,996 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare NATCO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare NATCO PHARMA With: LUPIN LTD  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  PFIZER  



Today's Market

Sensex Trades Rangebound; Metal, Pharma Stocks Top Losers(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading below the dotted line.

Related Views On News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 18, 2018 03:17 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS